On January 17, the gastric bypass stent system developed by Hangzhou Tongee Medical Technology Co., Ltd. was approved by the National Medical Products Administration (NMPA) and was granted the certificate of the world’s first innovative Class III medical device for intestinal intervention treatment of obesity!

Gastric bypass stent system, as an innovative therapy, is characterized by “l(fā)ess trauma, easy operation, zero damage to the human body structure, easy removal, repeatable implantation” and other advantages over traditional treatment options. It achieves a conceptual leap from “reduced intake” to “reduced absorption”, pioneering a new treatment approach for weight reduction, filling the challenging gap between weight loss relying on drugs and weight loss relying on surgery. Gastric bypass stent system has become an important supplement to medical weight loss, contributing to the stepped weight loss pattern of “l(fā)ifestyle intervention → drugs → interventional therapy → surgery”.

The research on gastric bypass stent system has lasted for over a decade, and a significant amount of animal tests and human clinical trials have provided sufficient evidence-based medical support for the safety and efficacy of the gastric bypass stent system. The development and refinement of the gastric bypass stent system has been a progressively innovating process, supported by high-level rigor and meticulousness, which can be described as “perfection achieved over years”.

The approval of the gastric bypass stent system marks an important step in metabolic disease intervention in China and even in the world. From the situation of overseas technology leading the industry to the emergence of Chinese innovative technology in the international arena, the approved gastric bypass stent system, as an original and world-leading innovative technology in China, highlights the continuous improvement of China’s research capability, and will further fuel up technological innovation in the entire medical industry in China.

The grant of the certificate for the innovative Class III medical device represents a new starting point for Tongee Medical and also marks an important milestone of Tongee Medical’s full entry into the field of metabolic disease treatment. We firmly believe that in the future, with the application of proper intestinal technology to the core treatment and key diagnostic decision-making processes of more metabolic diseases, it will empower more doctors to save more lives and help billions of patients with various metabolic diseases around the world regain their health!